Beijing Strong Biotechnologies Inc

Beijing Strong Biotechnologies, Inc. announced on September 11 that it has recently received a Medical Device Registration Certificate issued by the Beijing Municipal Medical Products Administration. The product is named Type I Collagen Amino-Terminal Extension Peptide Assay Kit, Magnetic Particle Chemiluminescence Immunoassay Method. The registration certificate number is Jing Xie Zhu Zhun 20262400350, the registration category is Class II, and it is valid from the approval date until September 8, 2031. The kit is used for the in vitro quantitative determination of total type I collagen amino-terminal extension peptide, Total-P1NP, in human serum or plasma. The company stated that obtaining this registration certificate enriches its product line in the chemiluminescence segment of in vitro diagnostics, helps enhance its core competitiveness and market expansion capabilities, and will have a positive impact on future operations. The company also cautioned that actual sales will depend on market promotion results, and the specific impact on performance cannot yet be predicted.

Beijing Strong Biotechnologies, Inc. announced that its folate assay kit, using magnetic particle chemiluminescence immunoassay, has received a medical device registration certificate from the Beijing Municipal Medical Products Administration. The registration certificate number is Jing Xie Zhu Zhun 20262400323, the registration category is Class II, and it is valid until August 26, 2031. The product is used for the in vitro quantitative determination of folate in human serum or plasma. The company stated that obtaining this registration certificate will enrich its product line in the in vitro diagnostics chemiluminescence field and help enhance its core competitiveness, but the specific impact on future operations cannot yet be predicted.

Jiugiang Bio disclosed its semi-annual report for 2026, with total operating revenue of 679 million yuan in the first half, up 1.55% year-on-year, and net profit attributable to the parent of 210 million yuan, up 20.02% year-on-year. The company plans to distribute a cash dividend of 1.5 yuan per 10 shares, tax included, to all shareholders. During the reporting period, non-GAAP net profit was 206 million yuan, up 18.86% year-on-year, net cash flow from operating activities was 247 million yuan, up 1.11% year-on-year, basic earnings per share was 0.36 yuan, and weighted average return on equity was 5.59%. The company is mainly engaged in the production and sales of in vitro diagnostic reagents and instruments.

Jiugang Biology announced plans to distribute a cash dividend of 1.5 yuan, tax included, for every 10 shares to all shareholders, with an estimated total payout of 87.39 million yuan. In the first half of 2026, Jiugang Biology achieved revenue of 679 million yuan and net profit attributable to the parent company of 210 million yuan.

Beijing Strong Biotechnologies has recently obtained two Medical Device Registration Certificates from the Beijing Medical Products Administration. The Antithrombin III Assay Kit (Chromogenic Substrate Method) and the Osteocalcin Assay Kit (Magnetic Particle Chemiluminescence Immunoassay) are both Class II devices, valid until July 5, 2031. They are used for the in vitro quantitative determination of antithrombin III activity in human plasma and osteocalcin levels in human serum or plasma, respectively. The company stated that obtaining these certificates enriches its product lines in the coagulation and chemiluminescence segments, helping to enhance core competitiveness and market expansion capabilities. However, actual sales will depend on future market promotion results, and the impact on performance cannot yet be predicted.